Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Gross Profit (2023 - 2025)

Historic Gross Profit for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $29.0 million.

  • Iovance Biotherapeutics' Gross Profit rose 717.91% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 12639.79%. This contributed to the annual value of $40.1 million for FY2024, which is 51893.16% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Gross Profit stood at $29.0 million, which was up 717.91% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Gross Profit registered a high of $29.0 million during Q3 2025, and its lowest value of -$6.5 million during Q1 2024.
  • Moreover, its 3-year median value for Gross Profit was -$339500.0 (2024), whereas its average is $4.8 million.
  • The largest annual percentage gain for Iovance Biotherapeutics' Gross Profit in the last 5 years was 135496.18% (2025), contrasted with its biggest fall of 717.91% (2025).
  • Over the past 3 years, Iovance Biotherapeutics' Gross Profit (Quarter) stood at -$3.9 million in 2023, then skyrocketed by 232.84% to $5.2 million in 2024, then skyrocketed by 461.81% to $29.0 million in 2025.
  • Its last three reported values are $29.0 million in Q3 2025, $3.3 million for Q2 2025, and -$417000.0 during Q1 2025.